Disease · MONDO_0020108
Trials50
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 20 of 50
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03764618 | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA | Phase 3 | 90 | 2023-05-25 | Warm Antibody Autoimmune Hemolytic Anemia | FOSTAMATINIB DISODIUM | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03538041 | A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia | Phase 2 | 25 | 2022-09-22 | Autoimmune Hemolytic Anemia | PARSACLISIB | Its record names the disease | ClinicalTrials.gov |
| NCT03226678 | Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD) | Phase 2 | 24 | 2024-12-12 | Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease | PEGCETACOPLAN | Its record names the disease | ClinicalTrials.gov |
| NCT05073458 | Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia | Phase 3 | 13 | 2025-01-15 | Warm Autoimmune Hemolytic Anemia (wAIHA) | PARSACLISIB | Its record names the disease | ClinicalTrials.gov |
| NCT03075878 | A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA) | Phase 1/2 | 8 | 2020-05-13 | Warm Autoimmune Hemolytic Anemia | ORILANOLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04253236 | To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA). | Phase 2 | 5 | 2022-07-28 | Warm Autoimmune Hemolytic Anemia | BATOCLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04657094 | Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia | Phase 2 | 4 | 2024-05-29 | Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Warm Antibody Autoimmune Hemolytic Anemia | ACALABRUTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT07518277 | A Multicenter, Prospective, Randomized Controlled Study Comparing Glucocorticoid Combined With Sirolimus With Monotherapy of Glucocorticoid in the Treatment of Newly Diagnosed Mild Autoimmune Hemolytic Anemia | Not applicable | 216 | Autoimmune Hemolytic Anemia (AIHA) | SIROLIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT05931718 | Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia | 200 | Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, Chronic Idiopathic Neutropenia, Autoimmune Neutropenia, Myelodysplastic Syndromes, Cold Agglutinin Disease | EPOETIN ALFA, LUSPATERCEPT | Its record names the disease | ClinicalTrials.gov | ||
| NCT05786573 | A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre) | Phase 3 | 134 | Warm Autoimmune Hemolytic Anemia | OBEXELIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT04119050 | Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia | Phase 2/3 | 118 | Warm Autoimmune Hemolytic Anemia | NIPOCALIMAB | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov | |
| NCT04138927 | A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | Phase 3 | 90 | Warm Antibody Autoimmune Hemolytic Anemia | FOSTAMATINIB DISODIUM | Its record names the disease | ClinicalTrials.gov | |
| NCT05648968 | A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia | Phase 3 | 90 | Warm Autoimmune Hemolytic Anemia (wAIHA) | IANALUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT07086976 | A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia | Phase 3 | 90 | Autoimmune Haemolytic Anaemia | RILZABRUTINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT00309881 | Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT) | Phase 2 | 75 | Chronic Lymphocytic Leukemia | CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, PREDNISONE, RITUXIMAB, VINCRISTINE SULFATE | Its record names the disease | ClinicalTrials.gov | |
| NCT01134432 | Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic Anemia | Phase 3 | 65 | Anemia, Hemolytic, Autoimmune | PREDNISOLONE, RITUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT07603557 | Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE) | Phase 2 | 52 | Chronic Immune Thrombocytopenia, Autoimmune Hemolytic Anemia | CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, ZOLACABTAGENE AUTOLEUCEL | Its record names the disease | ClinicalTrials.gov | |
| NCT03827603 | Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia | Phase 2 | 50 | AIHA - Warm Autoimmune Hemolytic Anemia | IBRUTINIB, RITUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT07453368 | Orelabrutinib in the Treatment of Relapsed/Refractory AIHA | Phase 2 | 50 | Autoimmune Hemolytic Anemia (AIHA) | ORELABRUTINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT05694312 | Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL | Phase 2 | 45 | Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Monoclonal B-Cell Lymphocytosis CLL-Type | IBRUTINIB | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0020108/trials